Therefore, the anti-PDGFR-specific agents crenolanib and olaratumab were tested as treatments for patients with imatinib-resistant GIST, mainly those with PDGFR mutation [25,26]. This evidence concerns the gene PDGFRB and gastrointestinal stromal tumor.